LEADER 01214nam0-22003491i-450- 001 990000814210403321 005 20080903101749.0 035 $a000081421 035 $aFED01000081421 035 $a(Aleph)000081421FED01 035 $a000081421 100 $a20020821d1992----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa-------001yy 200 1 $aCosimo Fanzago e il marmo commesso fra Abruzzo e Campania nell'età barocca$eatti del convegno$ePescocostanzo e Sulmona25-27 settembre 1992$fa cura di Vittorio Casale 210 $aL'Aquila$cLibreria Colacchi$d1995 215 $a274 p., [27] p. di tav.$cill.$d24 cm 300 $aIn testa alla cop.: Deputazione di Storia Patria negli Abruzzi 610 0 $aFanzago, Cosimo 610 0 $aIntarsi marmorei$aAbruzzo$aSec. 17.-18. 610 0 $aIntarsi marmorei$aCampania$aSec. 17.-18. 702 1$aCasale,$bVittorio 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000814210403321 952 $aSEZ.NA B 1857$b11260$fFARBC 952 $a12.279$b3123$fDARST 959 $aFARBC 959 $aDARST 996 $aCosimo Fanzago e il marmo commesso fra Abruzzo e Campania nell'età barocca$9347435 997 $aUNINA LEADER 05456nam 2200661Ia 450 001 9910785092303321 005 20200520144314.0 010 $a1-281-11194-5 010 $a9786611111946 010 $a0-08-055652-3 035 $a(CKB)1000000000411123 035 $a(EBL)328558 035 $a(OCoLC)476125925 035 $a(SSID)ssj0000201577 035 $a(PQKBManifestationID)11182304 035 $a(PQKBTitleCode)TC0000201577 035 $a(PQKBWorkID)10245323 035 $a(PQKB)10115200 035 $a(Au-PeEL)EBL328558 035 $a(CaPaEBR)ebr10204367 035 $a(CaONFJC)MIL111194 035 $a(OCoLC)437197004 035 $a(MiAaPQ)EBC328558 035 $a(EXLCZ)991000000000411123 100 $a20070821d2008 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMetabolic syndrome and psychiatric illness$b[electronic resource] $einteractions, pathophysiology, assessment and treatment /$fScott D. Mendelson 205 $a1st ed. 210 $aAmsterdam ;$aBoston $cElsevier/Academic Press$d2008 215 $a1 online resource (221 p.) 300 $aDescription based upon print version of record. 311 $a0-12-374240-4 320 $aIncludes bibliographical references and index. 327 $aFront Cover; Metabolic Syndrome and Psychiatric Illness; Copyright Page; Table of Contents; ACKNOWLEDGMENTS; FOREWORD; Chapter 1 Gerald Reaven and the Discovery of Syndrome X; References; Chapter 2 Factors that Contribute to Metabolic Syndrome; Genetics; Carbohydrates and the Glycemic Index; Fructose; Fiber; Fatty Acids and how they Differ; Saturated Fat; Omega-3 and Omega-6; Trans Fats; Micronutrients; Salt; Exercise; Smoking and Drinking; Obesity; References; Chapter 3 The Pathophysiology of Metabolic Syndrome; Insulin; Insulin Resistance and Compensatory Hyperinsulinemia 327 $aThe Rise of the Adipocyte Leptin; Adipocytes, Insulin, and Metabolic Syndrome; Muscle; The Liver; The Liver, Fat, and Insulin Resistance; Non-alcoholic Fatty Liver Disease; Hormonal Interactions in the Liver; Peroxisome Proliferation Activating Receptors; Inflammation; Oxidative Stress; Lipotoxicity; Asymmetrical Dimethylarginine; Stress and Cortisol; References; Chapter 4 Metabolic Syndrome and Psychiatric Illness; Major Depression; Insulin Resistance and Major Depression; Stress; Inflammation; Obesity; The Liver, Metabolic Syndrome and Major Depression; Cholesterol and Suicide 327 $aSeasonal Affective Disorder Bipolar Affective Disorder; Anxiety Disorders; Schizophrenia; Metabolic Syndrome, Schizophrenia, and the NMDA Receptor; Fibromyalgia; Polycystic Ovary Disease; References; Chapter 5 Psychiatric Medications and Metabolic Syndrome; Antidepressants; Mood Stabilizers; Atypical Antipsychotics; Atypical Antipsychotics and Weight Gain; Genetics and Atypical Antipsychotic-induced Weight Gain; Mechanisms of Atypical Antipsychotic-induced Weight Gain; Atypical Antipsychotics and Insulin Resistance; Effects of Atypical Antipsychotics on Serum Lipids 327 $aAtypical Antipsychotics and Diabetes Hyperprolactinemia; Guidelines for Monitoring Patients on Atypical Antipsychotics; Add-on Treatments to Counter Weight Gain and Metabolic Syndrome; Difficult Choices Must be Made; References; Chapter 6 Depression, Metabolic Syndrome, and Heart Disease; Dysrhythmias; Heart Failure; Ischemic Heart Disease and Myocardial Infarction; Platelet Hyperactivity; Inflammation; Stress; Lipid Abnormalities; Does Treating Major Depression Reduce Cardiac Risk?; References; Chapter 7 Metabolic Syndrome, Insulin and Alzheimer's Disease; The Stages of Alzheimer's Disease 327 $aPlaques and TanglesInsulin and Alzheimer's Disease; Insulin-Degrading Enzyme and Amyloid; Insulin and Tangled Tau; Inflammation and Alzheimer's Disease; References; Chapter 8 Metabolic Syndrome, Sleep, and Sex; Sleep Apnea; Hypoxia; Sleep Apnea, Stress, and Metabolic Syndrome; Smuggling, Snoring and the Velopharynx; Sleep, Mood and Glycogen Synthase Kinase-3 (GSK-3); Sleep Apnea and Alzheimer's Disease; Inadequate Sleep and Altered Sleep Schedules; Metabolic Syndrome and Sex; References; Chapter 9 Diets for Weight Loss and Metabolic Syndrome; Low-Fat, High-Carbohydrate Diets 327 $aA Few Words about Protein 330 $aMetabolic syndrome is a set of risk factors that includes: abdominal obesity, a decreased ability to process glucose (insulin resistance), dyslipidemia (unhealthy lipid levels), and hypertension. Patients who have this syndrome have been shown to be at an increased risk of developing cardiovascular disease and/or type 2 diabetes. Metabolic syndrome is a common condition that goes by many names (dysmetabolic syndrome, syndrome X, insulin resistance syndrome, obesity syndrome, and Reaven's syndrome).This is the first book to fully explain the relationships between psychiatric illness, Me 606 $aMetabolic syndrome$xComplications 606 $aMental illness$xComplications 615 0$aMetabolic syndrome$xComplications. 615 0$aMental illness$xComplications. 676 $a616.89/071 22 676 $a616.89071 700 $aMendelson$b Scott D$01521835 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910785092303321 996 $aMetabolic syndrome and psychiatric illness$93761254 997 $aUNINA